366-70-1 Usage
Description
Procarbazine hydrochloride, also known as Matulane, is a white to pale yellow crystalline powder with a slight odor. It is an antineoplastic chemotherapy drug that is used for the treatment of various types of cancer, including Hodgkin's lymphoma. It works by inhibiting DNA replication and has a rapid and complete absorption after oral administration. The drug is metabolized in the liver and crosses the blood-brain barrier. The major mechanisms of resistance to procarbazine hydrochloride include enhanced activity of DNA-repair enzymes. Adverse effects of the drug may include myelosuppression, nausea, vomiting, hypersensitivity, flu-like symptoms, amenorrhea, azoospermia, and central nervous system effects such as lethargy, confusion, neuropathies, and seizures.
Uses
1. Used in Anticancer Applications:
Procarbazine hydrochloride is used as an antineoplastic agent for the treatment of Hodgkin's disease, non-Hodgkin's lymphomas, and lung cancer. It is particularly effective against solid malignancies and works by inhibiting DNA replication, leading to the breaking of DNA strands and preventing tumor growth and progression.
2. Used in Hodgkin's Lymphoma Treatment:
Procarbazine hydrochloride is used as a component of the MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) regimen, which is a standard chemotherapy treatment for Hodgkin's lymphoma. It is effective in treating this type of cancer due to its antineoplastic properties and ability to inhibit DNA replication.
3. Used in Brain Cancer Treatment:
Procarbazine hydrochloride is used as an antineoplastic agent for the treatment of brain cancer. Its ability to cross the blood-brain barrier makes it a valuable drug in this application, as it can directly target cancer cells in the brain and inhibit their growth.
4. Used in Mycosis Fungoides Treatment:
Procarbazine hydrochloride is used as an antineoplastic agent for the treatment of mycosis fungoides, a rare type of skin cancer. Its antineoplastic properties and DNA replication inhibition make it an effective treatment option for this condition.
5. Used in DNA Repair Inhibition:
Procarbazine hydrochloride is used as a DNA replication inhibitor, which contributes to its antineoplastic effects. By inhibiting DNA replication, the drug prevents cancer cells from dividing and proliferating, ultimately leading to the suppression of tumor growth.
Air & Water Reactions
In the presence of moisture or in aqueous solution undergoes oxidation by atmospheric oxygen. Water soluble.
Reactivity Profile
Procarbazine hydrochloride is very sensitive to light. Stability is highest in aqueous acid and decreases with increasing pH. Degrades rapidly in alcoholic media and more slowly in aqueous media .
Fire Hazard
Flash point data for Procarbazine hydrochloride are not available; however, Procarbazine hydrochloride is probably combustible.
Safety Profile
Confirmed carcinogen
with experimental carcinogenic,
neoplastigenic, tumorigenic, and teratogenic
data. Poison by an unspecified route.
Moderately toxic by ingestion,
subcutaneous, intravenous, and
intraperitoneal routes. Experimental
reproductive effects. Mutation data
reported. When heated to decomposition it
emits very toxic fumes of NOx and HCl.
Used as a chemotherapeutic agent.
Potential Exposure
Procarbazine is available in capsule
form. The primary use of this drug is as an antineoplastic
agent in the treatment of advanced Hodgkin’s disease, and
oat-cell carcinoma of the lung. The hydrochloride com-
pound is used in treatment. The FDA approved use of pro-
carbazine hydrochloride in 1969 and indicated that the drug
should be used as an adjunct to standard therapy. Possible
exposure occurs during manufacture of the drug and direct
exposure during its subsequent administration to patients.
Some of the metabolites of procarbazine hydrochloride are
both carcinostatic and carcinogenic.
Veterinary Drugs and Treatments
In veterinary medicine, procarbazine is used as part of MOPP protocols
(mechlorethamine, vincristine, procarbazine, prednisone) to
treat lymphomas in dogs and cats. It may be of benefit in treating
granulomatous meningoencephalitis (GME) in dogs.
Shipping
UN2811 Toxic solids, organic, n.o.s., Hazard
Class: 6.1; Labels: 6.1-Poisonous materials, Technical
Name Required.
Incompatibilities
Incompatible with oxidizers (chlorates,
nitrates, peroxides, permanganates, perchlorates, chlorine,
bromine, fluorine, etc.); contact may cause fires or
explosions. Keep away from alkaline materials, strong
bases, strong acids, oxoacids, epoxides.
Waste Disposal
It is inappropriate and
possibly dangerous to the environment to dispose of
expired or waste drugs and pharmaceuticals by flushing
them down the toilet or discarding them to the trash.
Household quantities of expired or waste pharmaceuticals
may be mixed with wet cat litter or coffee grounds,
double-bagged in plastic, discard in trash. Larger quanti-
ties shall carefully take into consideration applicable
DEA, EPA, and FDA regulations. If possible return the
pharmaceutical to the manufacturer for proper disposal
being careful to properly label and securely package
the material. Alternatively, the waste pharmaceutical
shall be labeled, securely packaged and transported by a
state licensed medical waste contractor to dispose by
burial in a licensed hazardous or toxic waste landfill
or incinerator.
Check Digit Verification of cas no
The CAS Registry Mumber 366-70-1 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 3,6 and 6 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 366-70:
(5*3)+(4*6)+(3*6)+(2*7)+(1*0)=71
71 % 10 = 1
So 366-70-1 is a valid CAS Registry Number.
InChI:InChI=1/C12H19N3O.ClH/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3;/h4-7,9,13-14H,8H2,1-3H3,(H,15,16);1H
366-70-1Relevant articles and documents
Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
-
, (2008/06/13)
A method for the treatment of emesis in a mammal, which method comprises administering to said mammal an emesis inhibiting amount of a compound which depletes serotonin in the brain of mammals; among which are compounds having the formula: STR1 wherein, R is selected from hydrogen, loweralkyl, trifluoromethyl, carboxyl, or loweralkoxycarbonyl; R1 and R2 are hydrogen or loweralkyl; Z is trifluoromethyl or halogen; the optical isomers and pharmaceutically acceptable salts thereof; two of the preferred compounds of the invention are fenfluramine and norfenfluramine.